Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5268128
Max Phase: Preclinical
Molecular Formula: C88H107ClN34O17
Molecular Weight: 1912.04
Associated Items:
ID: ALA5268128
Max Phase: Preclinical
Molecular Formula: C88H107ClN34O17
Molecular Weight: 1912.04
Associated Items:
Canonical SMILES: CC(=O)Nc1cc(C(=O)Nc2cc(C(=O)Nc3cc(C(=O)Nc4cn(C)c(C(=O)Nc5cn(C)c(C(=O)NCCC(=O)Nc6cn(C)c(C(=O)NCCCC(=O)Nc7cc(C(=O)Nc8cc(C(=O)Nc9cc(C(=O)NCCC(=O)Nc%10cc(C(=O)Nc%11cn(C)c(C(=O)Nc%12cc(C(=O)NCCC(=O)NCCCN(C)C)n(C)c%12)n%11)n(C)c%10)n(C)c9)n(C)c8)n(C)c7)n6)n5)n4)n(C)c3)n(C)c2)n(C)c1.Cl
Standard InChI: InChI=1S/C88H106N34O17.ClH/c1-48(123)94-49-28-59(113(6)36-49)79(130)98-53-33-62(117(10)40-53)82(133)100-55-35-64(118(11)42-55)84(135)108-67-46-122(15)76(106-67)88(139)109-68-47-120(13)74(104-68)86(137)93-26-21-72(127)102-65-44-119(12)73(103-65)85(136)90-22-16-18-70(125)95-50-29-60(114(7)37-50)80(131)99-54-34-61(116(9)41-54)81(132)97-52-31-57(111(4)39-52)78(129)92-25-20-71(126)96-51-30-63(115(8)38-51)83(134)107-66-45-121(14)75(105-66)87(138)101-56-32-58(112(5)43-56)77(128)91-24-19-69(124)89-23-17-27-110(2)3;/h28-47H,16-27H2,1-15H3,(H,89,124)(H,90,136)(H,91,128)(H,92,129)(H,93,137)(H,94,123)(H,95,125)(H,96,126)(H,97,132)(H,98,130)(H,99,131)(H,100,133)(H,101,138)(H,102,127)(H,107,134)(H,108,135)(H,109,139);1H
Standard InChI Key: CITZMMPSHBVHJR-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1912.04 | Molecular Weight (Monoisotopic): 1910.8475 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Wang M, Ma X, Zhou K, Mao H, Liu J, Xiong X, Zhao X, Narva S, Tanaka Y, Wu Y, Guo C, Sugiyama H, Zhang W.. (2021) Discovery of Pyrrole-imidazole Polyamides as PD-L1 Expression Inhibitors and Their Anticancer Activity via Immune and Nonimmune Pathways., 64 (9.0): [PMID:33949196] [10.1021/acs.jmedchem.1c00120] |
Source(1):